List view / Grid view
23 September 2014 | By Andrew Lloyd & Associates
A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines...
23 September 2014 | By The Institute of Cancer Research
Even long stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports...
23 September 2014 | By Horizon Discovery
Horizon Discovery Group plc announces its interim results for the six months ended 30 June 2014...
22 September 2014 | By Children’s Cancer Institute and Abcam plc
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development...
22 September 2014 | By Domain Therapeutics
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs...
22 September 2014 | By kdm communications
Innovative batch and flow reactors from leading manufacturer Syrris are proving advantageous for a variety of nanoparticle applications, offering scientists working in the field numerous benefits...
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.
22 September 2014 | By Kymab
Kymab Limited announced that the European Patent Office has granted Kymab's request to entirely revoke European Patent EP1,360,287B1, owned by Regeneron Pharmaceuticals Inc...
22 September 2014 | By Andrew Lloyd & Associates
GENTICEL announces that following the Supervisory Board’s meeting held on September 11, 2014, Mary Tanner has been appointed to the board as a new independently-acting member and as Audit Committee chairman...
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
19 September 2014 | By Nexstim
Nexstim Oy announces its intention to proceed with an Initial Public Offering of Nexstim on NASDAQ OMX First North Finland and NASDAQ OMX First North Sweden...
19 September 2014 | By Novo Nordisk
New analyses of Phase 3a IDegLira (insulin degludec /liraglutide; Xultophy®) DUAL™ study data show an early and substantial improvement in glycaemic control, and a beneficial weight profile in type 2 diabetes patients compared to insulin degludec...
19 September 2014 | By Andrew Lloyd & Associates
Bioxodes SA announces that it has successfully brought its lead product, Ir-CPI, through pre-clinical development confirming its potential as the first in a new class of antithrombotic medicines...
19 September 2014 | By BIogen Idec
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in adults with relapsing-remitting multiple sclerosis (RRMS) beyond the first year of the study...
18 September 2014 | By kdm communications
Tecan has launched the Freedom EVO® NGS workstation to simplify next-generation sequencing (NGS) sample preparation and PCR set-up...
